Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Dopexamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 3/20 | 0.97 |
| ▸ | DRD1 known ✓ | P21728 | 2/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.97 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.97 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.97 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.97 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.97 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.97 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.97 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.97 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.97 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.97 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 7/20 | 0.62 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.60 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dopexamine SCHEMBL123114 | 1.00 | ADRB2 (0.97) | ADRB2DRD1DRD3ADORA3CHRM1 | |
| Dopexamine SCHEMBL29390436 | 1.00 | ADRB2 (0.97) | ADRB2DRD1DRD3ADORA3CHRM1 | |
| SCHEMBL7272201 | 0.98 | ADRB2 (1.00) | ADRB2DRD1DRD3ADORA3CHRM1 | |
| Dopexamine SCHEMBL122233 | 0.98 | ADRB2 (1.00) | ADRB2DRD1DRD3ADORA3CHRM1 | |
| Dopexamine SCHEMBL29711811 | 0.98 | ADRB2 (1.00) | ADRB2DRD1DRD3ADORA3CHRM1 | |
| SCHEMBL7278498 | 0.98 | ADRB2 (1.00) | ADRB2DRD1DRD3ADORA3CHRM1 | |
| Dopexamine SCHEMBL5605569 | 0.98 | ADRB2 (1.00) | ADRB2DRD1DRD3ADORA3CHRM1 | |
| Dopexamine SCHEMBL5464371 | 0.97 | ADRB2 (0.97) | ADRB2DRD1DRD3ADORA3CHRM1 | |
| Bromide SCHEMBL7280381 | 0.97 | ADRB2 (0.97) | ADRB2DRD1DRD3ADORA3CHRM1 | |
| Bromide SCHEMBL7278354 | 0.97 | ADRB2 (0.97) | ADRB2DRD1DRD3ADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105362214-B | A kind of dopexamine hydrochloride injection and preparation method thereof | 沈阳双鼎制药有限公司 | 2018-08-14 | — | — | CN | claimed |
| CN-105001103-B | A kind of synthetic method of dopexamine hydrochloride intermediate | 江苏同禾药业有限公司 | 2017-11-03 | — | — | CN | claimed |
| CN-105362214-A | Dopexamine hydrochloride injection and preparation method thereof | Shenyang shuangding pharmaceutical co ltd | 2016-03-02 | — | — | CN | claimed |
| CN-105272861-A | Dopexamine hydrochloride and novel preparation method thereof | Shenyang shuangding pharmaceutical co ltd | 2016-01-27 | — | — | CN | claimed |
| CN-105001103-A | Method for synthesizing Dopexamino intermediate | JIANGSU TOHOPE PHARMACEUTICAL CO LTD | 2015-10-28 | — | — | CN | claimed |
| CN-101531601-B | Method for separating and analyzing dopexamine hydrochloride by using HPLC method | BEIJING D VENTURE PHARM TECH | 2014-07-09 | — | — | CN | claimed |
| CN-102295568-B | Preparation method of dopexamine hydrochloride | JINAN CHENGHUI SHUANGDA CHEMICAL CO LTD | 2013-09-04 | — | — | CN | claimed |
| CN-102295568-A | Preparation method of dopexamine hydrochloride | — | 2011-12-28 | — | — | CN | claimed |
| CN-101606926-A | A kind of pharmaceutical composition that contains dopexamine hydrochloride | BEIJING D VENTUREPHARM TECHNOL (CN) | 2009-12-23 | — | — | CN | claimed |
| CN-101531601-A | Method for separating and analyzing dopexamine hydrochloride by using HPLC method | BEIJING D VENTURE PHARM TECH | 2009-09-16 | — | — | CN | claimed |
| CN-1813693-A | Dopexamine hydrochloride injection and its preparing method | SHANDONG CHANGFU JIEJING PHARM (CN) | 2006-08-09 | — | — | CN | claimed |
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | NIPPON CHEMIPHAR CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TAKASAKI UNIV OF HEALTH AND WELFARE (JP) | 2026-01-01 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| WO-2000050020-A2 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0909183-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | Neuromedica, Inc. (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | HRH2, HRH4, HRH1 | ADRB2 39/4885DRD1 3665/4885DRD3 2640/4885 |
| US-20260000678-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOM ASSOCIATED WITH PSEUDO-ALLERGIC REACTION | TRPV1, TRPV4, TRPV5 | ADRB2 537/4885DRD1 2717/4885DRD3 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.